Skip to content
Screener

Sana Biotechnology SANA Retained Earnings

Retained Earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.32B+25.8%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$14.59B+42.3%
Gilead Sciences logo
Gilead SciencesGILD
$2.2B-80.6%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$2.07B-37.9%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$2.05B-9.2%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$6.28B-4.9%

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$979.59M+32.1%
Enterprise value$971.11M+28.5%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Reported directly by Sana Biotechnology in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216769
Line itemMarch 31, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2026 and December 31, 2025--
Common stock, $0.0001 par value; 750,000 shares authorized; 269,817 and 266,732 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively2727
Additional paid-in capital2,015,4412,009,845
Accumulated other comprehensive income (loss)(2)28
Accumulated deficit(1,896,226)(1,849,016)
Total stockholders' equity119,240160,884
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$373,593$416,890

Item 1. Financial Statements

FAQ

What is Sana Biotechnology's retained earnings?
Sana Biotechnology (SANA) reported retained earnings of -$1.9B in Q1 2026.
How has Sana Biotechnology's retained earnings changed year-over-year?
Sana Biotechnology's retained earnings decreased by 14.6% year-over-year, from -$1.65B to -$1.9B.
What is the long-term trend for Sana Biotechnology's retained earnings?
Over 5 years (2020 to 2025), Sana Biotechnology's retained earnings has grown at a 33.9% compound annual growth rate (CAGR), from -$429.43M to -$1.85B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Sana Biotechnology's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude